However, PKC inhibitors have failed as anti-tumour agents in clinical trials, many cancer-associated loss-of-function PKC mutations have been identified, and recent evidence indicates that PKC generally acts as a tumour suppressor. This evidence concerns the gene PRRT2 and neoplasm.